CA2498267A1 - Methode pour traiter la dyserection et augmenter la libido chez l'homme - Google Patents
Methode pour traiter la dyserection et augmenter la libido chez l'hommeInfo
- Publication number
- CA2498267A1 CA2498267A1 CA002498267A CA2498267A CA2498267A1 CA 2498267 A1 CA2498267 A1 CA 2498267A1 CA 002498267 A CA002498267 A CA 002498267A CA 2498267 A CA2498267 A CA 2498267A CA 2498267 A1 CA2498267 A1 CA 2498267A1
- Authority
- CA
- Canada
- Prior art keywords
- testosterone
- steroid
- men
- enhancer
- isopropyl myristate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract 52
- 201000001881 impotence Diseases 0.000 title claims abstract 6
- 208000010228 Erectile Dysfunction Diseases 0.000 title claims abstract 5
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims abstract 52
- 229960003604 testosterone Drugs 0.000 claims abstract 26
- 239000000203 mixture Substances 0.000 claims abstract 12
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 claims abstract 5
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Natural products CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims abstract 3
- 230000035936 sexual power Effects 0.000 claims abstract 3
- 229940094720 viagra Drugs 0.000 claims abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 27
- 150000003431 steroids Chemical class 0.000 claims 14
- 239000003623 enhancer Substances 0.000 claims 11
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical group O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 9
- 239000002562 thickening agent Substances 0.000 claims 9
- 229920002125 Sokalan® Polymers 0.000 claims 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims 6
- 229930195729 fatty acid Natural products 0.000 claims 6
- 239000000194 fatty acid Substances 0.000 claims 6
- 239000003961 penetration enhancing agent Substances 0.000 claims 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 6
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims 4
- 230000037361 pathway Effects 0.000 claims 4
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 claims 4
- 206010052649 Primary hypogonadism Diseases 0.000 claims 3
- 210000001015 abdomen Anatomy 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 150000004665 fatty acids Chemical class 0.000 claims 3
- 230000003054 hormonal effect Effects 0.000 claims 3
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 claims 2
- 229960000711 alprostadil Drugs 0.000 claims 2
- 229960004046 apomorphine Drugs 0.000 claims 2
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims 2
- CXWQXGNFZLHLHQ-DPFCLETOSA-N apomorphine hydrochloride Chemical compound [H+].[H+].O.[Cl-].[Cl-].C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 CXWQXGNFZLHLHQ-DPFCLETOSA-N 0.000 claims 2
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 claims 2
- -1 papavaerine Chemical compound 0.000 claims 2
- 229960001476 pentoxifylline Drugs 0.000 claims 2
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 claims 2
- 229960001999 phentolamine Drugs 0.000 claims 2
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229960002639 sildenafil citrate Drugs 0.000 claims 2
- 229960000317 yohimbine Drugs 0.000 claims 2
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 claims 2
- IVOJLNSQLGMYAO-AWEZNQCLSA-N (3s)-3-[[6-[[(3-methylsulfonylphenyl)sulfonylamino]methyl]pyridine-3-carbonyl]amino]-4-oxobutanoic acid Chemical compound CS(=O)(=O)C1=CC=CC(S(=O)(=O)NCC=2N=CC(=CC=2)C(=O)N[C@@H](CC(O)=O)C=O)=C1 IVOJLNSQLGMYAO-AWEZNQCLSA-N 0.000 claims 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 206010040880 Skin irritation Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 230000007246 mechanism Effects 0.000 abstract 1
- 230000036556 skin irritation Effects 0.000 abstract 1
- 231100000475 skin irritation Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2498267A CA2498267C (fr) | 2001-08-29 | 2001-08-29 | Methode pour traiter la dyserection et augmenter la libido chez l'homme |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2498267A CA2498267C (fr) | 2001-08-29 | 2001-08-29 | Methode pour traiter la dyserection et augmenter la libido chez l'homme |
| CA002420895A CA2420895C (fr) | 2000-08-30 | 2001-08-29 | Methode pour traiter la dyserection et augmenter la libido chez l'homme |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002420895A Division CA2420895C (fr) | 2000-08-30 | 2001-08-29 | Methode pour traiter la dyserection et augmenter la libido chez l'homme |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2498267A1 true CA2498267A1 (fr) | 2002-03-07 |
| CA2498267C CA2498267C (fr) | 2010-10-26 |
Family
ID=34427647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2498267A Expired - Lifetime CA2498267C (fr) | 2001-08-29 | 2001-08-29 | Methode pour traiter la dyserection et augmenter la libido chez l'homme |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2498267C (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006061689A1 (fr) * | 2004-12-10 | 2006-06-15 | Alan Drizen | Systeme d'administration de medicaments topiques |
-
2001
- 2001-08-29 CA CA2498267A patent/CA2498267C/fr not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006061689A1 (fr) * | 2004-12-10 | 2006-06-15 | Alan Drizen | Systeme d'administration de medicaments topiques |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2498267C (fr) | 2010-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2330188T3 (es) | Composicion farmaceutica en forma de gel o de solucion a base de dihidrotestoterona, su procedimiento de preparacion y sus utilizaciones. | |
| CA2646667C (fr) | Methode de traitement des bouffees de chaleur par des preparations transdermiquea ou transmucosiques | |
| US20030139384A1 (en) | Method for treating erectile dysfunction and increasing libido in men | |
| EP1510213B1 (fr) | Systèmes comprenant de la testostérone améliorants la pénétration et reduisants les irritations | |
| AU2001286995B2 (en) | Method for treating erectile dysfunction and increasing libido in men | |
| DK2398457T3 (en) | TOPICAL FORMULATION clobetasol propionate LOW DOSE FOR TREATMENT OF DISEASES skin and mucous membranes | |
| CA2419404A1 (fr) | Compositions et methodes de traitement de dysfonctionnements sexuels | |
| JP2004524267A5 (fr) | ||
| EP2173323B1 (fr) | Gel stimulant | |
| US5747070A (en) | Methods for the treatment of herpes virus infections | |
| US20130079304A1 (en) | Pharmaceutical Compositions for the Treatment of Fungal Infections | |
| US6500440B1 (en) | Topical preparation of alprostadil for the treatment of erectile dysfunction | |
| US10993934B2 (en) | Topical compositions of dutasteride | |
| CA2498267A1 (fr) | Methode pour traiter la dyserection et augmenter la libido chez l'homme | |
| WO2004030665A1 (fr) | Composition de gel transparent destine a l'administration de sodium de diclofenac a travers la peau | |
| RU2003108500A (ru) | Способ лечения эректильной дисфункции и повышения либидо у мужчин | |
| US20120238535A1 (en) | Topical formulation of low level clobetasol propionate for treating disorders of the skin and mucous membranes | |
| WO2002102385A1 (fr) | Compositions comprenant un inhibiteur de cgmp pde5 pour administration transdermique au tissu erectile du penis | |
| CN1491647A (zh) | 经皮式用于治疗阳痿和女性性冷淡并防治性病的组合物 | |
| US20090018214A1 (en) | Composition for Promoting Vascular Smooth Muscle Relaxation | |
| CN110996909A (zh) | 表面组合物 | |
| US20180147138A1 (en) | Transdermal liquid preparation | |
| US11141387B2 (en) | Memantine-containing transdermally absorbable liquid | |
| WO2016028903A1 (fr) | Compositions pharmaceutiques pour l'administration par voie transmuqueuse orale comprenant de la testostérone et un c-serm | |
| US20160051563A1 (en) | Oral Transmucosal Pharmaceutical Compositions including Testosterone and an Aromatase Inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20210830 |